AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6609270 — intervention group
Group type: EXPERIMENTAL
Intervention: New cuprophan hollow fiber dialyzers
Number of subjects: 11
Study 6609270 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin-fixed new dialyzers
Number of subjects: 11
Study 6609270 — intervention group
Group type: COMPARATOR
Intervention: Re-used dialyzers
Number of subjects: 11
Study 31032629 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (n=117): systematic discharge assessment with targeted advice
Number of subjects: 349
Study 31032629 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n=116): motivational conversation and home visit
Number of subjects: 349
Study 31032629 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=116)
Number of subjects: 349
Study 27542725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36
Study 27542725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36
Study 27542725 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS applied to the left PMC prior to SRTT training
Number of subjects: 36
Study 27542725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS applied during SRTT training
Number of subjects: 36
Study 27542725 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS applied during SRTT training
Number of subjects: 36
Study 27542725 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS applied during SRTT training
Number of subjects: 36
Study 25772587 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program, three times a week for 8 weeks
Number of subjects: 0
Study 25772587 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 0
Study 25451894 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 38
Study 25451894 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized wound care)
Number of subjects: 38
Study 22676466 — intervention group
Group type: EXPERIMENTAL
Intervention: Asha-Life intervention engaging with an HIV-trained village woman, Asha
Number of subjects: 68
Study 22676466 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 68
Study 21290835 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 131
Study 21290835 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 131
Study 21290835 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication and Acupuncture
Number of subjects: 131
Study 17541116 — intervention group
Group type: EXPERIMENTAL
Intervention: fast, left frontal rTMS given three times a week over 4-6 weeks
Number of subjects: 29
Study 17541116 — intervention group
Group type: COMPARATOR
Intervention: sham treatment
Number of subjects: 29
Study 15767642 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 330
Study 15767642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 330
Study 15767642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination (Anastrozole + Tamoxifen)
Number of subjects: 330
Study 15767642 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (Control)
Number of subjects: 330
Study 15767642 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (Control)
Number of subjects: 330
Study 11952187 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation and self‐control desensitization
Number of subjects: 0
Study 11952187 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 11952187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of applied relaxation, self‐control desensitization, and cognitive therapy
Number of subjects: 0
Study 11952187 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal treatment (suggested addition)
Number of subjects: 0
Study 9447851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 3 ng/ml
Number of subjects: 92
Study 9447851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl at 10 ng/ml
Number of subjects: 92
Study 9447851 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (various concentrations)
Number of subjects: 92
Study 7880699 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg kg‐1 (groups 1, 3, 5)
Number of subjects: 72
Study 7880699 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg kg‐1 (groups 2, 4, 6)
Number of subjects: 72
Study 7880699 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine antagonism at PTC 0 (group 1)
Number of subjects: 72
Study 7880699 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (groups 2, 4, 6)
Number of subjects: 72
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 440 mg
Number of subjects: 0
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 880 mg
Number of subjects: 0
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopherol 1320 mg
Number of subjects: 0
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic administration of dl‐alpha‐tocopherol (440, 880, or 1320 mg/d for 28 d)
Number of subjects: 0
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of treatment after day 28
Number of subjects: 0
Study 2000827 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 0
Study 6362322 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intracutaneous Dexon 6
Number of subjects: 57
Study 6362322 — intervention group
Group type: COMPARATOR
Intervention: Single knots of silk
Number of subjects: 57
Study 30569798 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning session (warm-up followed by small-sided games, accelerations and 2 x 50-m maximal sprints)
Number of subjects: 14
Study 30569798 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioning session (Experimental)
Number of subjects: 14
Study 30569798 — intervention group
Group type: COMPARATOR
Intervention: Control (no pre-loading session)
Number of subjects: 14
Study 30662575 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel FES group (n = 18)
Number of subjects: 48
Study 30662575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel FES group (n = 15)
Number of subjects: 48
Study 30662575 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 15)
Number of subjects: 48
Study 30662575 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-channel FES group
Number of subjects: 48
Study 30662575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel FES group
Number of subjects: 48
Study 30662575 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 48
Study 25677920 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily for 48 hours)
Number of subjects: 130
Study 25677920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 22354336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐recorded video tutorial
Number of subjects: 0
Study 22354336 — intervention group
Group type: EXPERIMENTAL
Intervention: Student self‐video
Number of subjects: 0
Study 22354336 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching method
Number of subjects: 0
Study 21272283 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to read during rapid serial visual presentation (RSVP) (n = 20)
Number of subjects: 36
Study 21272283 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to optimize reading eye movements (SM, sensomotoric training) (n = 16)
Number of subjects: 36
Study 20029518 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow postmeal walking for 15 min (W15)
Number of subjects: 14
Study 20029518 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow postmeal walking for 40 min (W40)
Number of subjects: 14
Study 20029518 — intervention group
Group type: COMPARATOR
Intervention: Control (seated)
Number of subjects: 14
Study 16483435 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intravenous ampiclox and vitamin B complex
Number of subjects: 278
Study 16483435 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B complex (placebo)
Number of subjects: 278
Study 15516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1453
Study 15516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex-smokers
Number of subjects: 1453
Study 15516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers (up to 14 cigarettes per day)
Number of subjects: 1453
Study 15516665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative smoking
Number of subjects: 1453
Study 10935688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg, four doses) with triazolam (0.125 mg)
Number of subjects: 0
Study 10935688 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (200 mg, four doses) with zolpidem (5.0 mg)
Number of subjects: 0
Study 10935688 — intervention group
Group type: COMPARATOR
Intervention: Placebo with triazolam (0.125 mg)
Number of subjects: 0
Study 10935688 — intervention group
Group type: COMPARATOR
Intervention: Placebo with zolpidem (5.0 mg)
Number of subjects: 0
Study 8848989 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg/day
Number of subjects: 24
Study 8848989 — intervention group
Group type: COMPARATOR
Intervention: Transdermal clonidine weekly
Number of subjects: 24
Study 1335403 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute altitude challenge (3450 m)
Number of subjects: 10
Study 1335403 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exposure to mild hypoxia (14.5% oxygen)
Number of subjects: 10
Study 6366560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone alternated with chlorambucil every other month for six months
Number of subjects: 67
Study 6366560 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment only (Control)
Number of subjects: 67
Study 6366560 — intervention group
Group type: COMPARATOR
Intervention: Control group (Symptomatic treatment only)
Number of subjects: 67
Study 29785466 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified atWork intervention (MAW)
Number of subjects: 1011
Study 29785466 — intervention group
Group type: COMPARATOR
Intervention: Original atWork intervention (OAW)
Number of subjects: 1011
Study 29448828 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine‐tryptophan‐ketoglutarate with terminal warm blood cardioplegia
Number of subjects: 109
Study 29448828 — intervention group
Group type: COMPARATOR
Intervention: Histidine‐tryptophan‐ketoglutarate only
Number of subjects: 109
Study 26965932 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus‐eluting Endeavor Sprint stent (E‐ZES)
Number of subjects: 828
Study 26965932 — intervention group
Group type: COMPARATOR
Intervention: Bare‐metal stent (BMS)
Number of subjects: 828
Study 24485080 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of gel of lidocaine 2% intrarectal with 50mg tramadol (2 tablets)
Number of subjects: 60
Study 24485080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of lidocaine 2% injected at the level of periprostatics laterals and apical areas
Number of subjects: 60
Study 22791802 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-based tetrastarch HES infusion
Number of subjects: 13
Study 22791802 — intervention group
Group type: COMPARATOR
Intervention: Balanced solution-based HES infusion
Number of subjects: 13
Study 19712201 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hepatitis C patients (CHC group)
Number of subjects: 62
Study 19712201 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 62
Study 18060924 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal Thermometry Group
Number of subjects: 225
Study 18060924 — intervention group
Group type: COMPARATOR
Intervention: Standard Therapy Group
Number of subjects: 225
Study 15943224 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg genistein
Number of subjects: 40
Study 15943224 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg genistein
Number of subjects: 40
Study 15943224 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg genistein
Number of subjects: 40
Study 15943224 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg genistein
Number of subjects: 40
Study 12847933 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face case management
Number of subjects: 0
Study 12847933 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecommunication case management
Number of subjects: 0
Study 12847933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 10435880 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus GHRH (100 microg, i.v. in bolus)
Number of subjects: 14
Study 10435880 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (100 mg p.o.) before GHRH injection
Number of subjects: 14
Study 10606109 — intervention group
Group type: EXPERIMENTAL
Intervention: MULTI-LINK DUET stents
Number of subjects: 270
Study 2093422 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine-raubasine
Number of subjects: 40
Study 838992 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA), 50 mug four times daily
Number of subjects: 26
Study 838992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 838992 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (BDA)
Number of subjects: 26
Study 30904872 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise intervention (exercise classes)
Number of subjects: 0
Study 30904872 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 28741013 — intervention group
Group type: EXPERIMENTAL
Intervention: LUCAS CPR
Number of subjects: 1274
Study 28741013 — intervention group
Group type: COMPARATOR
Intervention: Manual CPR
Number of subjects: 1274
Study 28741013 — intervention group
Group type: EXPERIMENTAL
Intervention: Early LUCAS CPR
Number of subjects: 1274
Study 28741013 — intervention group
Group type: EXPERIMENTAL
Intervention: Late LUCAS CPR
Number of subjects: 1274
Study 25305230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cloxacillin (2 g IV) or clindamycin (600 mg IV)
Number of subjects: 325
Study 25305230 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 325
Study 23874575 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly administered antiretroviral therapy (DAART)
Number of subjects: 107
Study 23874575 — intervention group
Group type: COMPARATOR
Intervention: Self-administered therapy (SAT)
Number of subjects: 107
Study 23874575 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DAART and SAT
Number of subjects: 107
Study 21267804 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam 4.5 g i.v. (single-dose)
Number of subjects: 51
Study 21267804 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg or cotrimoxazol 960 mg i.v./p.o. (5 days)
Number of subjects: 51
Study 21267804 — intervention group
Group type: COMPARATOR
Intervention: Control group (varied administration and duration of different antibiotics)
Number of subjects: 51
Study 21267804 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 51
Study 21267804 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam group
Number of subjects: 51
Study 19799843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (45 microg)
Number of subjects: 353
Study 19799843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (15 microg)
Number of subjects: 353
Study 19799843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-adjuvanted whole-virus vaccine (5 microg)
Number of subjects: 353
Study 19799843 — intervention group
Group type: COMPARATOR
Intervention: Intradermal whole-virus vaccine
Number of subjects: 353
Study 19799843 — intervention group
Group type: COMPARATOR
Intervention: Virosomal vaccine
Number of subjects: 353
Study 16902841 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg training on a cycle-ergometer for 45 min/day, 4 days/week for six weeks
Number of subjects: 28
Study 16902841 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg training
Number of subjects: 28
Study 16902841 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 14728939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal bleeding
Number of subjects: 8507
Study 14728939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal bleeding with altered bowel habit
Number of subjects: 8507
Study 14728939 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated rectal bleeding
Number of subjects: 8507
Study 11297722 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n = 16)
Number of subjects: 35
Study 11297722 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 35
Study 9106123 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (20 mg daily)
Number of subjects: 10
Study 9106123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotype 1 (n = 38, subtypes 1a [27] and 1b [11])
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus genotypes 2a (n = 1), 2b (n = 3), 3a (n = 20), and 5a (n = 1)
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe disease hemophiliacs
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in circulating major genotype and serotype
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from one subtype to another
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of inactivated clotting factor
Number of subjects: 63
Study 7930698 — intervention group
Group type: EXPERIMENTAL
Intervention: Coinfected with human immunodeficiency virus
Number of subjects: 63
Study 3794874 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose gentamicin therapy
Number of subjects: 21
Study 3794874 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment for 10 days
Number of subjects: 21
Study 29970654 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 144
Study 29970654 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy (OE)
Number of subjects: 144
Study 29970654 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Complication Index (CCI)
Number of subjects: 144
Study 28282689 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange
Number of subjects: 1224
Study 28282689 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 1224
Study 28282689 — intervention group
Group type: COMPARATOR
Intervention: Water immersion
Number of subjects: 1224
Study 26213156 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ)
Number of subjects: 14
Study 22502816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (ADT)
Number of subjects: 173
Study 22502816 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT)
Number of subjects: 173
Study 20546945 — intervention group
Group type: EXPERIMENTAL
Intervention: Xin-yi-san (XYS)
Number of subjects: 108
Study 20546945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 18164459 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Number of subjects: 0
Study 15899109 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25mg IV
Number of subjects: 12
Study 15899109 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.25mg IV with aprepitant 125 mg on day 1 and 80 mg on days 2 and 3
Number of subjects: 12
Study 15899109 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.25mg IV with aprepitant
Number of subjects: 12
Study 15899109 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25mg IV and palonosetron/aprepitant regimen
Number of subjects: 12
Study 12559781 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured antiviral drug treatment interruptions (STIs) with therapeutic HIV immunizations
Number of subjects: 25
Study 12559781 — intervention group
Group type: COMPARATOR
Intervention: Structured antiviral drug treatment interruptions (STIs) without therapeutic HIV immunizations
Number of subjects: 25
Study 10326816 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 39
Study 10326816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 vol%
Number of subjects: 12
Study 7574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.0 vol%
Number of subjects: 12
Study 7574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1.5 vol%
Number of subjects: 12
Study 7574016 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 2.0 vol%
Number of subjects: 12
Study 1659189 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine (ddI) administered orally twice daily at a total daily dose of 750 mg or 1,500 mg for 12 weeks
Number of subjects: 30
Study 6992834 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) and placebo cream topically
Number of subjects: 90
Study 6992834 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatic retinoid (Ro 10‐9359) orally (0.50‐0.66 mg/kg body weight) with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Number of subjects: 90
Study 6992834 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules with 0.1% triamcinolone acetonide and 5% salicylic acid in lanette wax cream
Number of subjects: 90
Study 30745183 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational therapy
Number of subjects: 84
Study 30745183 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 84